interstitial collagens
Recently Published Documents


TOTAL DOCUMENTS

41
(FIVE YEARS 0)

H-INDEX

19
(FIVE YEARS 0)

2008 ◽  
Vol 77 (2) ◽  
pp. 867-876 ◽  
Author(s):  
Jürgen Baumert ◽  
Karl-Hermann Schmidt ◽  
Annett Eitner ◽  
Eberhard Straube ◽  
Jürgen Rödel

ABSTRACT Chlamydia pneumoniae infection has been associated with chronic obstructive airway disease (COPD), asthma, and atherosclerosis. Inflammation and airway remodeling in asthma and COPD result in subepithelial fibrosis that is characterized by the deposition of interstitial collagens and fibronectin. The progression of atherosclerosis is also accompanied by an increased production of interstitial collagens in the intima. As shown by reverse transcription-PCR and immunoblotting, infection of human fibroblasts and smooth muscle cells by C. pneumoniae TW-183 downregulated the expression of type I and III collagen and fibronectin, whereas the level of type IV collagen remained unchanged. Conditioned medium from infected fibroblasts as well as epithelial WISH cells also reduced the expression of interstitial collagens and fibronectin in uninfected cells. In experiments using blocking antibodies, beta interferon was found to contribute to the inhibitory effects of conditioned medium collected from infected fibroblasts. In contrast, downregulation of matrix protein expression by conditioned medium from epithelial cells was caused by interleukin-1α, which was not secreted from fibroblasts following chlamydial infection. C. pneumoniae-mediated inhibition of collagen and fibronectin expression was diminished following transfection of fibroblasts with specific small interfering RNA targeting the transcription factor CCAAT/enhancer-binding protein β. The downregulation of interstitial collagens and fibronectin by the Chlamydia-induced host cell cytokine response may modulate tissue remodeling processes in airway diseases. In atherosclerosis the inhibition of collagen synthesis by C. pneumoniae infection may promote plaque vulnerability, thereby increasing the risk of plaque rupture.


2002 ◽  
Vol 278 (9) ◽  
pp. 7270-7277 ◽  
Author(s):  
Wan-Ming Zhang ◽  
Jarmo Käpylä ◽  
J. Santeri Puranen ◽  
C. Graham Knight ◽  
Carl-Fredrik Tiger ◽  
...  

2001 ◽  
Vol 277 (5) ◽  
pp. 3242-3246 ◽  
Author(s):  
Rajan Somasundaram ◽  
Martin Ruehl ◽  
Benjamin Schaefer ◽  
Monika Schmid ◽  
Renate Ackermann ◽  
...  

2001 ◽  
Vol 237 (1) ◽  
pp. 116-129 ◽  
Author(s):  
Carl-Fredrik Tiger ◽  
Francoise Fougerousse ◽  
Gunilla Grundström ◽  
Teet Velling ◽  
Donald Gullberg

1997 ◽  
Vol 16 (2) ◽  
pp. 76-77 ◽  
Author(s):  
E. Ohuchi ◽  
K. Imai ◽  
Y. Fujii ◽  
H. Sato ◽  
M. Seiki ◽  
...  

1997 ◽  
Vol 92 (2) ◽  
pp. 103-112 ◽  
Author(s):  
R. Alcolado ◽  
M. J. P. Arthur ◽  
J. P. Iredale

1. Liver fibrosis is a common sequel to diverse liver injuries. It is characterized by an accumulation of interstitial collagens and other matrix components. The hepatic stellate cell is pivotal to the pathogenic process. Fibrotic liver injury results in activation of the hepatic stellate cell which undergoes a phenotypic change to a proliferative myofibroblast-like cell which synthesizes excess interstitial collagens and other matrix components. 2. The process of initiation of activation and its perpetuation result from complex, often interrelated series of signalling mechanisms which converge on this effector cell. Such mechanisms include alterations in matrix resulting in changed cell—matrix interactions and stimulation by cytokines released from damaged hepatocytes, infiltrating inflammatory cells, Kupffer cells and matrix. Foremost among the profibrotic cytokines is transforming growth factor β1. 3. Once the hepatic stellate cell is activated the preceding matrix changes and recurrent injurious stimuli will perpetuate the activated state. 4. Despite the accumulation of excess collagens, the liver retains a capacity for matrix degradation. This capacity may be overwhelmed and any secreted matrix remodelling enzymes may be inhibited by the concurrently secreted tissue inhibitors of metallo-proteinase-1 and α2-macroglobulin. 5. Our understanding of the molecular pathogenesis of liver fibrosis is increasing. It is anticipated that this knowledge will provide novel therapeutic avenues to treat this disease process.


1997 ◽  
Vol 272 (4) ◽  
pp. 2446-2451 ◽  
Author(s):  
Eiko Ohuchi ◽  
Kazushi Imai ◽  
Yutaka Fujii ◽  
Hiroshi Sato ◽  
Motoharu Seiki ◽  
...  

1995 ◽  
Vol 246 (2) ◽  
pp. 284-294 ◽  
Author(s):  
Francoise Gaill ◽  
Karlheinz Mann ◽  
Hanna Wiedemann ◽  
Jürgen Engel ◽  
Rupert Timpl

Sign in / Sign up

Export Citation Format

Share Document